BACKGROUND: The decision to use induction antibody therapy in kidney transplantation is often based on perceived patient risk, as no objective biomarker has been shown to predict the effectiveness of such therapy. Because pretransplant T-cell alloreactivity has been shown to increase the risk of poor posttransplant outcome, and because induction therapy is directed at alloreactive T cells, we hypothesized that antibody induction would preferentially benefit patients with high pretransplant antidonor T-cell immunity. METHODS: In a retrospective analysis of 130 patients who had enrolled in an immune monitoring study, we correlated acute rejection rates, renal allograft function, and use of antibody induction therapy with donor-reactive interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) frequencies assessed pre and postkidney transplantation. RESULTS: Of the 32 ELISPOT (+) patients, eight received induction therapy and had no rejection. Of the remaining 24 ELISPOT (+) patients with no induction therapy, acute rejection occurred in 11 (46%), (P=0.02). Twelve month glomerular filtration rate was significantly higher in the eight patients who received induction therapy (P=0.0001). Posttransplant conversion to a negative ELISPOT assay occurred in 86% of patients who received induction therapy vs. 35% of patients who did not (P=0.02). In the ELISPOT (-) cohort, acute rejection rates ( approximately 15%) and glomerular filtration rates were similar in the 98 patients regardless of induction therapy. CONCLUSIONS: Our results suggest that antibody induction therapy preferentially benefits kidney transplant candidates with strong pretransplant donor-reactive cellular immunity. If confirmed prospectively, pretransplant ELISPOT assessments could be used to guide decision making regarding induction therapy.
BACKGROUND: The decision to use induction antibody therapy in kidney transplantation is often based on perceived patient risk, as no objective biomarker has been shown to predict the effectiveness of such therapy. Because pretransplant T-cell alloreactivity has been shown to increase the risk of poor posttransplant outcome, and because induction therapy is directed at alloreactive T cells, we hypothesized that antibody induction would preferentially benefit patients with high pretransplant antidonor T-cell immunity. METHODS: In a retrospective analysis of 130 patients who had enrolled in an immune monitoring study, we correlated acute rejection rates, renal allograft function, and use of antibody induction therapy with donor-reactive interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) frequencies assessed pre and postkidney transplantation. RESULTS: Of the 32 ELISPOT (+) patients, eight received induction therapy and had no rejection. Of the remaining 24 ELISPOT (+) patients with no induction therapy, acute rejection occurred in 11 (46%), (P=0.02). Twelve month glomerular filtration rate was significantly higher in the eight patients who received induction therapy (P=0.0001). Posttransplant conversion to a negative ELISPOT assay occurred in 86% of patients who received induction therapy vs. 35% of patients who did not (P=0.02). In the ELISPOT (-) cohort, acute rejection rates ( approximately 15%) and glomerular filtration rates were similar in the 98 patients regardless of induction therapy. CONCLUSIONS: Our results suggest that antibody induction therapy preferentially benefits kidney transplant candidates with strong pretransplant donor-reactive cellular immunity. If confirmed prospectively, pretransplant ELISPOT assessments could be used to guide decision making regarding induction therapy.
Authors: X Préville; M Flacher; B LeMauff; S Beauchard; P Davelu; J Tiollier; J P Revillard Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: N M van Besouw; A H M M Balk; M van Vliet; P H van der Meide; A P W M Maat; T van Gelder; C C Baan; W Weimar Journal: Transplant Proc Date: 2002-11 Impact factor: 1.066
Authors: Jason A Crompton; Troy Somerville; Lonnie Smith; Jacke Corbett; Edward Nelson; John Holman; Fuad S Shihab Journal: Pharmacotherapy Date: 2003-04 Impact factor: 4.705
Authors: F Vincenti; R Kirkman; S Light; G Bumgardner; M Pescovitz; P Halloran; J Neylan; A Wilkinson; H Ekberg; R Gaston; L Backman; J Burdick Journal: N Engl J Med Date: 1998-01-15 Impact factor: 91.245
Authors: Yvon Lebranchu; Frank Bridoux; Matthias Büchler; Yannick Le Meur; Isabelle Etienne; Olivier Toupance; Bruno Hurault de Ligny; Guy Touchard; Bruno Moulin; Patrick Le Pogamp; Olivier Reigneau; Michel Guignard; Gérard Rifle Journal: Am J Transplant Date: 2002-01 Impact factor: 8.086
Authors: Britta S Gebauer; Donald E Hricik; Aymen Atallah; Kathryn Bryan; Jocelyn Riley; Magdalena Tary-Lehmann; Neil S Greenspan; Cora Dejelo; Bernhard O Boehm; Bernhard J Hering; Peter S Heeger Journal: Am J Transplant Date: 2002-10 Impact factor: 8.086
Authors: James R Cassuto; Matthew H Levine; Peter P Reese; Roy D Bloom; Simin Goral; Ali Naji; Peter L Abt Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: P J E J van de Berg; S L Yong; S D Koch; N Lardy; K A M I van Donselaar-van der Pant; S Florquin; F J Bemelman; R A W van Lier; I J M ten Berge Journal: Clin Exp Immunol Date: 2012-05 Impact factor: 4.330
Authors: L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio Journal: Am J Transplant Date: 2011-05-12 Impact factor: 8.086
Authors: I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin Journal: Am J Transplant Date: 2013-05-24 Impact factor: 8.086